{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:03:01Z","timestamp":1649095381668},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T00:00:00Z","timestamp":1445990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0140853","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T20:30:55Z","timestamp":1446064255000},"page":"e0140853","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01263860","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qingxian","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoshuang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingshou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyu","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiumin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,10,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"JH Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/rmv.371","article-title":"Clinical consequences of hepatitis C virus infection","volume":"13","author":"F Zoulim","year":"2003","journal-title":"Rev Med Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/jvh.12339","article-title":"Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue","volume":"21","author":"H Razavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref5","unstructured":"ICTVOnline website. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/talk.ictvonline.org\/ictv_wikis\/w\/sg_flavi\/35.table-1-confirmed-hcv-genotypessubtypes-november-2014.aspx\" xlink:type=\"simple\">http:\/\/talk.ictvonline.org\/ictv_wikis\/w\/sg_flavi\/35.table-1-confirmed-hcv-genotypessubtypes-november-2014.aspx<\/ext-link>"},{"key":"ref6","first-page":"153","article-title":"High prevalence of Hepatitis C virus genotype 6 in Vietnam","volume":"27","author":"DA Pham","year":"2009","journal-title":". Asian Pac J Allergy Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1111\/j.1469-0691.2011.03665.x","article-title":"High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People&apos;s Democratic Republic","volume":"17","author":"JM H\u00fcbschen","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000318884","article-title":"Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand","volume":"54","author":"S Akkarathamrongsin","year":"2011","journal-title":"Intervirology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/jhep.2002.36781","article-title":"Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome","volume":"36","author":"AT Dev","year":"2002","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1096-9071(199610)50:2<168::AID-JMV10>3.0.CO;2-I","article-title":"Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong","volume":"50","author":"LE Prescott","year":"1996","journal-title":"J Med Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2893.2010.01280.x","article-title":"New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors","volume":"18","author":"Y Fu","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e28006","DOI":"10.1371\/journal.pone.0028006","article-title":"HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China: phylogeographic analyses","volume":"7","author":"Y Fu","year":"2012","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Y Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"EASL recommendations on treatment of hepatitis C 2014","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"E Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/jgh.12398","article-title":"Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection","volume":"29","author":"H Rao","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1099\/vir.0.029124-0","article-title":"IL-28B predicts response to chronic hepatitis C therapy\u2014fine-mapping and replication study in Asian populations","volume":"92","author":"H Ochi","year":"2011","journal-title":"J Gen Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"ML Yu","year":"2008","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.trsl.2006.04.006","article-title":"Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy","volume":"148","author":"ML Yu","year":"2006","journal-title":"Transl Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/hep.21917","article-title":"Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response","volume":"46","author":"SM Kamal","year":"2007","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"ML Yu","year":"2007","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C","volume":"129","author":"M Von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","article-title":"Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response","volume":"135","author":"P Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia","volume":"44","author":"S Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1440-1746.2009.06163.x","article-title":"Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1","volume":"25","author":"OT Tsang","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/hep.23889","article-title":"Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6","volume":"52","author":"KD Lam","year":"2010","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2893.2010.01373.x","article-title":"Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a","volume":"18","author":"YQ Zhou","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1369-1600.2009.00148.x","article-title":"Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients","volume":"14","author":"N Ebner","year":"2009","journal-title":"Addict Biol"},{"key":"ref32","unstructured":"U.S. Department of Healths and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, 2010. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\" xlink:type=\"simple\">http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE<\/ext-link>"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"A Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"SJ Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/368217","article-title":"Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1","volume":"187","author":"CK Hui","year":"2003","journal-title":"J Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2011.12.020","article-title":"A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C","volume":"56","author":"PT Thu Thuy","year":"2012","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1572-0241.2008.01793.x","article-title":"Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin","volume":"103","author":"MH Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"A Kau","year":"2008","journal-title":"J Hepatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"ACCELERATE investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"ML Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"V Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"A Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jmv.23876","article-title":"Interleukin-28b CC genotype predicts early treatment response and CT\/TT genotypes predicts non-response in patients infected with HCV genotype 3","volume":"86","author":"AC Gupta","year":"2014","journal-title":"J Med Virol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.3748\/wjg.v19.i47.8924","article-title":"Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients","volume":"19","author":"A Mangia","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","article-title":"Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6","volume":"17","author":"NH Nguyen","year":"2010","journal-title":"J Viral Hepat"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/592579","article-title":"Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial","volume":"47","author":"CH Liu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/MCG.0b013e31820d35e3","article-title":"Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: Results from the WIN-R trial","volume":"45","author":"KQ Hu","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ajg.2009.635","article-title":"Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C","volume":"105","author":"P Vutien","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","article-title":"Systematic review: Asian patients with chronic hepatitis C infection","volume":"37","author":"LH Nguyen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"MP Manns","year":"2001","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0140853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:36:27Z","timestamp":1540031787000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0140853"}},"subtitle":[],"editor":[{"given":"Dimitrios","family":"Paraskevis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,28]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0140853","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,28]]}}}